miR-449, identified through antiandrogen exposure, mitigates functional biomarkers associated with ovarian cancer risk

Xia Wang, Ho-Hyung Woo, Michelle Wei, Steven Gibson, Mitzi Miranda, Demaretta Rush, Janiel Cragun, Wenxin Zheng, Guang Yao, Setsuko K Chambers · 2024

Read miR-449, identified through antiandrogen exposure, mitigates functional biomarkers associated with ovarian cancer risk by Xia Wang, Ho-Hyung Woo, Michelle Wei, Steven Gibson, Mitzi Miranda, Demaretta Rush, Janiel Cragun, Wenxin Zheng, Guang Yao, Setsuko K Chambers (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11611913.txt.

Description

Xia Wang and co-authors trace how a hormone-blocking drug may lower ovarian cancer risk in women at high inherited risk. The drug, flutamide, blocks male hormone signals, a pathway now tied to this cancer's start. Their 2024 study began with tissue from high-risk women, some treated with the drug and some not, plus tissue from low-risk women for comparison.

Drug treatment brought the tissues' small RNA profile back toward the low-risk pattern, lifting a family called miR-449. In lab cells, the drug raised those same RNAs, and adding copies of them cut levels of two proteins that drive the cancer: the hormone receptor itself and a growth signal receiver. Cancer cells also moved less. The authors say the drug fights the pathway twice over, and may suit prevention for women with low miR-449.

Catalog record

CREATORXia Wang, Ho-Hyung Woo, Michelle Wei, Steven Gibson, Mitzi Miranda, Demaretta Rush, Janiel Cragun, Wenxin Zheng, Guang Yao, Setsuko K Chambers
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE43 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11611913

Browse the full library · About the Tower of Babel